C12N 15/11
Dna or rna fragments
Official title: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
C12N15/11 (Dna or rna fragments) appears on 22,973 US grants and 42,337 published applications in this corpus.
Search patents in C12N- Granted patents
- 22,973
- Published applications
- 42,337
- Assignees
- 8,674
- Inventors
- 59,164
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 9 | 0 |
| 1983 | 8 | 0 |
| 1984 | 11 | 0 |
| 1985 | 9 | 0 |
| 1986 | 11 | 0 |
| 1987 | 14 | 0 |
| 1988 | 27 | 0 |
| 1989 | 38 | 0 |
| 1990 | 45 | 0 |
| 1991 | 58 | 0 |
| 1992 | 84 | 0 |
| 1993 | 84 | 0 |
| 1994 | 86 | 0 |
| 1995 | 85 | 0 |
| 1996 | 175 | 0 |
| 1997 | 317 | 0 |
| 1998 | 398 | 0 |
| 1999 | 395 | 0 |
| 2000 | 393 | 0 |
| 2001 | 353 | 65 |
| 2002 | 338 | 367 |
| 2003 | 271 | 876 |
| 2004 | 191 | 827 |
| 2005 | 181 | 829 |
| 2006 | 228 | 694 |
| 2007 | 238 | 762 |
| 2008 | 208 | 739 |
| 2009 | 344 | 1088 |
| 2010 | 512 | 1108 |
| 2011 | 554 | 1199 |
| 2012 | 670 | 1197 |
| 2013 | 719 | 1283 |
| 2014 | 850 | 1523 |
| 2015 | 967 | 1674 |
| 2016 | 1005 | 1754 |
| 2017 | 1088 | 1804 |
| 2018 | 1165 | 2011 |
| 2019 | 1322 | 2597 |
| 2020 | 1396 | 2491 |
| 2021 | 1485 | 2696 |
| 2022 | 1462 | 3055 |
| 2023 | 1297 | 3002 |
| 2024 | 1344 | 3204 |
| 2025 | 1438 | 3118 |
| 2026 | 1099 | 2374 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 15/113Non-coding nucleic acids modulating the expression of genes13,160
- C12N 15/62Dna sequences coding for fusion proteins3,309
- C12N 15/111General methods applicable to biologically active non-coding nucleic acids3,198
- C12N 15/52Genes encoding for enzymes or proenzymes3,193
- C12N 15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high1,538
- C12N 15/117Nucleic acids having immunomodulatory properties520
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Pharmaceutical composition containing anionic drug, and preparation method therefor6 Oct 2026US 12,752,010 B2Samyang Holdings Corporation
- Expression of electrically conductive protein nanowires in Escherichia coli6 Oct 2026US 12,753,210 B2University of Massachusetts
- ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof6 Oct 2026US 12,753,215 B2
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Composition and Method for Topical Trans-spinal Delivery of Nucleic Acids and Small Molecules8 Oct 2026US 2026/0306414 A13P Biotechnologies, Inc.
- Active loading of biomolecular cargo into engineered vesicles8 Oct 2026US 2026/0306415 A1Northwestern University
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
Most cited
By later US patents
- Production of chimeric antibodies - a combinatorial approach1,367US 5,565,332 ACambridge Antibody Technology Limited · 1996
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Soybean transgenic event MON 87708 and methods of use thereof1,155US 8,501,407 B2Monsanto Technology LLC · 2013
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998